Research Analysts Offer Predictions for MMSI Q1 Earnings

Merit Medical Systems, Inc. (NASDAQ:MMSI) – Zacks Research boosted their Q1 2027 earnings estimates for shares of Merit Medical Systems in a research report issued on Thursday, August 20th. Zacks Research analyst Team now expects that the medical instruments supplier will post earnings per share of $0.88 for the quarter, up from their previous forecast of $0.84. The consensus estimate for Merit Medical Systems’ current full-year earnings is $3.84 per share. Zacks Research also issued estimates for Merit Medical Systems’ Q4 2027 earnings at $1.10 EPS.

Other analysts have also recently issued reports about the company. Barrington Research set a $114.00 price target on Merit Medical Systems in a research report on Friday, July 31st. JPMorgan Chase & Co. raised their price objective on Merit Medical Systems from $77.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings upgraded Merit Medical Systems from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Canaccord Genuity Group boosted their target price on Merit Medical Systems from $85.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Finally, Piper Sandler increased their target price on Merit Medical Systems from $96.00 to $106.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Eight investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.00.

Merit Medical Systems Price Performance

Shares of NASDAQ MMSI opened at $91.09 on Monday. The company has a 50 day simple moving average of $78.35 and a two-hundred day simple moving average of $72.66. Merit Medical Systems has a fifty-two week low of $59.74 and a fifty-two week high of $94.75. The company has a market capitalization of $5.44 billion, a price-to-earnings ratio of 37.64, a P/E/G ratio of 2.25 and a beta of 0.49. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.79 and a current ratio of 4.20.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. The company had revenue of $418.84 million during the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a net margin of 9.22% and a return on equity of 13.75%. Merit Medical Systems’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the company posted $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MMSI. AQR Capital Management LLC increased its position in shares of Merit Medical Systems by 7.3% during the first quarter. AQR Capital Management LLC now owns 16,361 shares of the medical instruments supplier’s stock valued at $1,730,000 after acquiring an additional 1,114 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Merit Medical Systems by 16.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 719,313 shares of the medical instruments supplier’s stock valued at $76,039,000 after acquiring an additional 103,878 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in Merit Medical Systems by 745.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after acquiring an additional 813 shares in the last quarter. First Trust Advisors LP boosted its stake in Merit Medical Systems by 24.8% during the 2nd quarter. First Trust Advisors LP now owns 59,215 shares of the medical instruments supplier’s stock valued at $5,535,000 after purchasing an additional 11,770 shares during the last quarter. Finally, Cerity Partners LLC boosted its stake in Merit Medical Systems by 9.1% during the 2nd quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock valued at $282,000 after purchasing an additional 251 shares during the last quarter. Institutional investors own 99.66% of the company’s stock.

Merit Medical Systems News Roundup

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Broad upward revisions to earnings forecasts: Zacks Research increased its FY2026 EPS estimate to $3.73 from $3.57, FY2027 to $4.01 from $3.82, and FY2028 to $4.32 from $4.12. Estimates were also raised for Q2 2027, Q3 2027, Q1 2028 and Q2 2028, suggesting improving expectations for Merit Medical’s earnings trajectory.
• Positive Sentiment: Growth initiatives are strengthening the investment case: New product launches, acquisitions and a broader portfolio of therapeutic medical products are supporting stronger growth and improving the company’s business mix. Recent quarterly results also showed revenue growth and an EPS beat, while the company raised its 2026 outlook. Should You Buy MMSI as Growth Improves but Valuation Stays Elevated?
• Neutral Sentiment: Short-interest data provides no meaningful signal: Reported short interest was zero shares both on August 10 and August 25, with a zero-day days-to-cover ratio. The reported “increase” is mathematically invalid, so the data does not indicate either meaningful short covering or rising bearish positioning.
• Negative Sentiment: Valuation and risk remain concerns: MMSI’s recent rally has left the stock trading at a premium valuation, increasing the need for continued earnings delivery. Analysts also cited tariff exposure and execution risks related to launches and acquisitions as potential headwinds. Can MMSI Sustain Its 22.2% Gain in the Past Month as Growth Improves?

Merit Medical Systems Company Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.